GCP
CGEM icon

GSA Capital Partners’s Cullinan Oncology CGEM Stock Holding History

GSA Capital Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,339
Closed -$616K – 1789
2026
Q1 		$616K Buy
43,339
+16,036
+59% +$206K 0.04% 787
2025
Q4 		$283K Buy
+27,303
New +$246K 0.02% 1197
2024
Q1 		– Sell
-10,246
Closed -$104K – 1646
2023
Q4 		$104K Buy
+10,246
New +$90.8K 0.01% 1390

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

GSA Capital Partners's CGEM Position: Q2 2026 in Review

GSA Capital Partners sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 43,339 shares — an estimated $616K sold.

GSA Capital Partners first reported a position in CGEM in Q4 2023 and held it in 3 quarters. The position peaked at $616K in Q1 2026. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • GSA Capital Partners reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 43,339 Cullinan Oncology shares in Q2 2026, an estimated $616K.
  • GSA Capital Partners first reported a position in Cullinan Oncology in Q4 2023 and held it in 3 quarters.
  • GSA Capital Partners's Cullinan Oncology position peaked at $616K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.